Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Assets (2019 - 2025)

Pulmonx has reported Assets over the past 7 years, most recently at $129.3 million for Q4 2025.

  • Quarterly Assets fell 20.61% to $129.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.3 million through Dec 2025, down 20.61% year-over-year, with the annual reading at $129.3 million for FY2025, 20.61% down from the prior year.
  • Assets was $129.3 million for Q4 2025 at Pulmonx, down from $138.3 million in the prior quarter.
  • Over five years, Assets peaked at $255.3 million in Q1 2021 and troughed at $129.3 million in Q4 2025.
  • The 5-year median for Assets is $189.1 million (2023), against an average of $190.4 million.
  • Year-over-year, Assets skyrocketed 246.44% in 2021 and then fell 20.61% in 2025.
  • A 5-year view of Assets shows it stood at $235.2 million in 2021, then dropped by 17.65% to $193.7 million in 2022, then dropped by 8.21% to $177.8 million in 2023, then fell by 8.4% to $162.8 million in 2024, then fell by 20.61% to $129.3 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Assets are $129.3 million (Q4 2025), $138.3 million (Q3 2025), and $147.2 million (Q2 2025).